Richard Guy - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Richard Guy's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Richard Guy
Verified
Biopharma Analyst, BioCentury
San Diego
Beats
medical devicesPharmaceuticals health and lawsuits
Economics, Business, Investment, Promotions
Content
By Richard Guy| BioCentury Verified ARTICLE | Emerging Company ProfileSan Francisco-based biotech is pursuing CNS diseases with three-stranded siRNAs that can target specific cell types within a tissue By Richard Guy, Biopharma AnalystSwitch Therapeutics is designing siRNAs that remain inactive until turned on inside cells containing a specific biomarker, allowing the company to selectively target cell types of interest within a tissue, without relying on surface proteins.
By Richard Guy| BioCentury Verified ARTICLE | Emerging Company ProfileCompany applying small molecule optimization techniques to peptides with a robotic synthesis platform By Richard Guy, Biopharma AnalystBacked with a $32 million series A round, Unnatural Products is the latest macrocycle company to spin out of Scott Lokey’s lab. The company’s empirical approach to macrocycle design, which entails synthesizing libraries of circular peptides using a bespoke robotic platform, has won it partnerships with Bridgebio and Merck.
By Richard Guy| BioCentury Verified ARTICLE | Market AccessIqvia’s latest report cites regulatory requirements, investment costs, and lack of market acceptance and predictability By Richard Guy, Biopharma AnalystPolicy failures and misaligned incentives have created a $156 billion “biosimilar void” that must be addressed to ensure the sustainability of the biosimilars market and to realize the cost savings that biosimilars can bring, according to a new report from Iqvia.
Company Info
BioCentury
BioCentury Inc. is a biotechnology-focused business intelligence and analytics company based in Redwood City, California. With over 30 years of experience, it specializes in providing strategic insights and data analysis tailored to the biopharma and biotech industries. The company reported a revenue of $16.2 million. BioCentury offers the BCIQ platform, which includes modules for tracking companies, products, and financial data. This platform helps clients identify trends, partnerships, and investment opportunities. Additionally, BioCentury provides analytical content that includes market trend analysis, visual data tools, and expert interviews. The company also facilitates networking through exclusive events and workshops, connecting C-suite executives and investors within the biopharma community.
Chicago, United States
+1 650-595-5333
Founded: 1992